scispace - formally typeset
D

David P. J. Turner

Researcher at University of Nottingham

Publications -  47
Citations -  2694

David P. J. Turner is an academic researcher from University of Nottingham. The author has contributed to research in topics: Neisseria meningitidis & Medicine. The author has an hindex of 22, co-authored 41 publications receiving 1719 citations. Previous affiliations of David P. J. Turner include Nottingham University Hospitals NHS Trust.

Papers
More filters
Journal ArticleDOI

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Katherine R. W. Emary, +69 more
- 10 Apr 2021 - 
TL;DR: A post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against B.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020 as discussed by the authors.
Journal ArticleDOI

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Xinxue Liu, +90 more
- 04 Sep 2021 - 
TL;DR: The Com-COV trial as discussed by the authors evaluated vaccine safety, reactogenicity, and immunogenicity of the BNT/ChAd schedule with a 28-day or 84-day prime-boost interval.
Journal ArticleDOI

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Amy Flaxman, +186 more
- 11 Sep 2021 - 
TL;DR: In this paper, the authors assessed the persistence of immunogenicity after a single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44-45 weeks) between the first and second dose, and response to a third dose as a booster given 28-38 weeks after the second dose.